Chugai Pharmaceutical Co., Ltd.
Phone: 81-(0)3-3281-6611
Fax: 81-(0)3-3281-6607
E-mail: Via Site
Web: https://www.chugai-pharm.co.jp
| Native name | 中外製薬株式会社 |
|---|---|
| Romanized name | Chūgai Seiyaku kabushiki gaisha |
| Type | Public KK |
| Traded as |
|
| Industry | Pharmaceutical Industry, Business import, production and development of drugs for medical sales |
| Founded | March 8, 1943 |
| Headquarters | Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo) |
| Key people | Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO |
| Revenue | 72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated (December 2007) |
| Parent | Hoffmann-La Roche (61.62%) |
| Website | www.chugai-pharm.co.jp (in Japanese) |
Chugai's mission is to create innovative drugs for the benefit of patients. As a research-based pharmaceutical company, Chugai specializes in the research, development, production and marketing of prescription pharmaceuticals. We have established the following business processes to create innovative medicines.
For detailed contact information visit location pages below.
Chugai Pharmaceutical Co., Ltd.'s locations around the world
Asia
Clinical Trials sponsored by Chugai Pharmaceutical Co., Ltd.
-
Chugai Pharmaceutical초대로 등록항인지질 증후군(APS) | 면역성 혈소판 감소증(ITP) | 피부근염(DM) | 수포성 천포창(BP) | 베체트 증후군(BS) | 면역 매개 괴사성 근육병증(IMNM)헝가리, 호주, 일본, 독일, 대만, 오스트리아, 불가리아, 크로아티아, 프랑스, 이탈리아, 네덜란드, 노르웨이, 포르투갈, 루마니아, 캐나다, 스페인, 체코, 폴란드, 터키 (Türkiye)
-
Chugai Pharmaceutical종료됨